Description of service
SSI will formulate the candidate antigens with their cationic liposomal adjuvant systems CAF01 or CAF09b. Short-term stability testing of the CAF-adjuvanted vaccines and physicochemical characterisation of the vaccines will be carried out.
8-12 weeks per project approx.
Grith Krøyer Wood
Development and characterisation of vaccine formulations with liposomal adjuvants CAF01 and CAF09b
Services do NOT include
In vivo testing of formulation is NOT included.
Optimised vaccine formulation with T cell inducing adjuvant and vaccine characterisation data.
Sample Requirements - input of users
The user must provide vaccine antigen ready to formulate with adjuvant, either lyophilised or in stable aqueous solution including documentation of physico-chemical properties and analytical methods to detect, quantify and characterise the antigen.
Ida Svahn Rasmussen